According to @StockMKTNewz, the United States and United Kingdom are reportedly nearing a deal that would raise UK prescription drug prices in exchange for avoiding tariffs, as reported by Seeking Alpha (source: @StockMKTNewz; Seeking Alpha). Traders are watching UK pharma names such as GSK (LSE:GSK), AstraZeneca (LSE:AZN), and Hikma (LSE:HIK) for potential pricing-power and margin read-throughs if the reported framework proceeds (source: @StockMKTNewz; Seeking Alpha). Reduced tariff risk can support GBP and UK equities, while healthcare price pressures may factor into BoE expectations, with risk sentiment spillovers keeping BTC and ETH on watch during trade-policy headlines (source: @StockMKTNewz; Seeking Alpha). US multinationals with UK exposure may also be monitored for incremental revenue impacts from higher UK list prices, alongside FX translation effects (source: @StockMKTNewz; Seeking Alpha).